Aikaterini Andreadi

Prof. Dr. Aikaterini Andreadi

Department of Systems Medicine, University of Rome Tor Vergata, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
Aikaterini AndreadiAikaterini Andreadi
Aikaterini Andreadi
ABAlfonso Bellia
Alfonso Bellia
NDNicola Di Daniele
Nicola Di Daniele
MMMarco Meloni
Marco Meloni
RLRenato Lauro
Renato Lauro
Davide LauroDavide Lauro
Davide Lauro

Verified
Journal Article
Open access
PDF file
Aikaterini AndreadiAikaterini Andreadi
Aikaterini Andreadi
SAStella Andreadi
Stella Andreadi
FTFederica Todaro
Federica Todaro
LILorenzo Ippoliti
Lorenzo Ippoliti
ABAlfonso Bellia
Alfonso Bellia
Davide LauroDavide Lauro
Davide Lauro
The circadian rhythm of cortisol, a key hormone essential for maintaining metabolic balance and stress homeostasis, is profoundly disrupted by night-shift work. This narrative review examines the physiological mechanisms underlying cortisol regulation, the effects of shift work on its circadian rhythm, the associated health risks, and potential mitigation strategies. Night-shift work alters the natural secretion pattern of cortisol, leading to dysregulation of the hypothalamic–pituitary–adrenal axis, which in turn can contribute to metabolic disorders, cardiovascular diseases, and impaired cognitive function. Understanding the physiological pathways mediating these changes is crucial for developing targeted interventions to mitigate the adverse effects of circadian misalignment. Potential strategies, such as controlled light exposure, strategic napping, and personalized scheduling, may help to stabilize cortisol rhythms and improve health outcomes. This review aims to provide insights that can guide future research and inform occupational health policies for night-shift workers by addressing these challenges.

21 June 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
DPDaniela Pollakova
Daniela Pollakova
Aikaterini AndreadiAikaterini Andreadi
Aikaterini Andreadi
Francesca PacificiFrancesca Pacifici
Francesca Pacifici
DMDavid Della Morte
David Della Morte
Davide LauroDavide Lauro
Davide Lauro
CTClaudio Tubili
Claudio Tubili
A protective effect of vegan diets on health outcomes has been observed in previous studies, but its impact on diabetes is still debated. The aim of this review is to assess the relationship between vegan diets and the risk for type 2 diabetes (T2D) along with its effect on glycemic control and diabetes-related complications. In accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta–Analyses) guidelines, Pubmed and Cochrane library databases were systematically searched for all relevant studies. Seven observational and eight randomized controlled (RCTs) studies were included. The methodological quality of studies was assessed using the National Institutes of Health quality assessment tool for observational cohort and cross-sectional studies and the Cochrane Risk of Bias Tool for RCTs. We found that a vegan diet is associated with lower T2D prevalence or incidence and in T2D patients decreases high glucose values and improves glucose homeostasis, as reported from the majority of included studies. This approach seems to be comparable to other recommended healthful eating models, but as it may have potential adverse effects associated with the long-term exclusion of some nutrients, appropriate nutritional planning and surveillance are recommended, particularly in specific groups of diabetic patients such as frail elderly, adolescents, and pregnant or breastfeeding women.

1 July 2019 in Respiratory Medicine
Verified
Journal Article
Closed access
PRPaola Rogliani
Paola Rogliani
MMMaria Gabriella Matera
Maria Gabriella Matera
LCLuigino Calzetta
Luigino Calzetta
NHNicola A. Hanania
Nicola A. Hanania
CPClive Page
Clive Page
DLDavide Lauro
Davide Lauro

1 July 2012 in Atherosclerosis
Verified
Journal Article
Closed access
ABAlfonso Bellia
Alfonso Bellia
SRStefano Rizza
Stefano Rizza
MLMarco Felice Lombardo
Marco Felice Lombardo
GDGiulia Donadel
Giulia Donadel
RFRossella Fabiano
Rossella Fabiano
Davide LauroDavide Lauro
Davide Lauro

Verified
Journal Article
Open access
PDF file
Aikaterini AndreadiAikaterini Andreadi
Aikaterini Andreadi
Saverio MuscoliSaverio Muscoli
Saverio Muscoli
RTRojin Tajmir
Rojin Tajmir
Marco MeloniMarco Meloni
Marco Meloni
CMCarolina Muscoli
Carolina Muscoli
Davide LauroDavide Lauro
Davide Lauro
Diabetes Mellitus is a multifactorial disease with a critical impact worldwide. During prediabetes, the presence of various inflammatory cytokines and oxidative stress will lead to the pathogenesis of type 2 diabetes. Furthermore, insulin resistance and chronic hyperglycemia will lead to micro- and macrovascular complications (cardiovascular disease, heart failure, hypertension, chronic kidney disease, and atherosclerosis). The development through the years of pharmacological options allowed us to reduce the persistence of chronic hyperglycemia and reduce diabetic complications. This review aims to highlight the specific mechanisms with which the new treatments for type 2 diabetes reduce oxidative stress and insulin resistance and improve cardiovascular outcomes.